Abstract:Wei Wei, 1, 2, &ast Haili Cao, 2, &ast Di Shen, 2 Xiyu Sun, 2 Zhenzhen Jia, 1 Mingzhen Zhang 1 1 School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, People's Republic of China; 2 Xi'an No.1 Hospital, Shaanxi Institute of Ophthalmology, Shaanxi Key Laboratory of Ophthalmology, Clinical Research Center for Ophthalmology Diseases of Shaanxi Province, First Affiliated Hospital of Northwestern University, Xi'an, Shaanxi, 710002, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhenzhen Jia; Mingzhen Zhang, Email ; Purpose: Dry eye disease (DED) is a multifactorial ocular surface disease with a rising incidence. Therefore, it is urgent to construct a reliable and efficient drug delivery system for DED treatment. Methods: In this work, we loaded C-dots nanozyme into a thermosensitive in situ gel to create C-dots@Gel, presenting a promising composite ocular drug delivery system to manage DED. Results: This composite ocular drug delivery system (C-dots@Gel) demonstrated the ability to enhance adherence to the corneal surface and extend the ocular surface retention time, thereby enhancing bioavailability. Furthermore, no discernible ocular surface irritation or systemic toxicity was observed. In the DED mouse model induced by benzalkonium chloride (BAC), it was verified that C-dots@Gel effectively mitigated DED by stabilizing the tear film, prolonging tear secretion, repairing corneal surface damage, and augmenting the population of conjunctival goblet cells. Conclusion: Compared to conventional dosage forms (C-dots), the C-dots@Gel could prolong exhibited enhanced retention time on the ocular surface and increased bioavailability, resulting in a satisfactory therapeutic outcome for DED. Keywords: dry eye disease, carbon dots nanozyme, thermosensitive in situ gel, composite ocular drug delivery system Dry eye disease (DED), also known as dry keratoconjunctivitis, is a prevalent multifactorial ocular surface disease that has impacted the daily functioning of millions of people around the world. 1 DED is characterized by a reduced volume of tears, abnormal corneal epithelial cells, and loss of conjunctival goblet cells, 2 resulting in compromised vision and quality of life. 3 Recent studies indicate a growing prevalence of DED worldwide, attributed to shifts in modern lifestyles, the popularity of corneal contact lenses, and environmental pollution. 4–6 As a kind of multifactorial inflammatory disease, the pathogenesis of DED remains poorly understood. Researchers have found that the reactive oxygen species (ROS) are linked to DED and are believed to contribute to its pathological development. 7–9 Therefore, targeting the overproduced reactive oxygen species (ROS) might be beneficial in efficiently managing inflammation in DED. 8,10 Under normal circumstances, the antioxidant system, consisting of endogenous antioxidant enzymes such as superoxide dismutase (SOD) and small molecules plays a crucial role in maintaining redox homeostasis. While the overproduction of ROS and reduced activity of anti-oxidase SOD have an unbalance in DED. Therefore, some eye drops with antioxidants, such as vitamin A, quercetin, and selenoprotein P, were reported to be effective in protecting the ocular surface from oxidative stress. 10 However, these treatments often yield unsatisfying results and have a high recurrence rate. At present, the major challenge in the drug-based treatment of DED is the limited residence time of conventional eye drops in the eye due to its unique structure, resulting in low bioavailability (< 5%). 11 High doses and frequent administration are required to achieve the expected outcome which brings increased side effects and poor patient compliance. 12 Therefore, it is crucial to explore novel and efficient DED therapies to minimize the frequency of administration, thereby improving ocular bioavailability and enhancing patient compliance. 13 To address the challenge, researchers have built diverse drug delivery systems, including polymer micelles, hydrogels, and metal frame materials, to improve the retention time and increase the permeability of drugs. 14–16 To update, various hydrogel dosages have been developed based on synthetic polymers or peptides. 17–21 Among them, in-situ gelling based on environmentally sensitive polymers would undergo structural changes in response to variations in specific conditions such as pH, temperature, and ionic strength. 10,20 In the con -Abstract Truncated-

Utilization of Nitrogen-Doped Graphene Quantum Dots to Neutralize ROS and Modulate Intracellular Antioxidant Pathways to Improve Dry Eye Disease Therapy

Antioxidant Carbon Dots Nanozyme Loaded in Thermosensitive in situ Hydrogel System for Efficient Dry Eye Disease Treatment

Dual-ROS-scavenging and dual-lingering nanozyme-based eye drops alleviate dry eye disease

Potential New Target for Dry Eye Disease—Oxidative Stress

Alleviation of dry eye syndrome with one dose of antioxidant, anti-inflammatory, and mucoadhesive lysine-carbonized nanogels

Suppression of NLRP3/Caspase-1/GSDMD Mediated Corneal Epithelium Pyroptosis Using Melatonin-Loaded Liposomes to Inhibit Benzalkonium Chloride-Induced Dry Eye Disease

Rosmarinic acid-grafted gelatin nanogels for efficient diquafosol delivery in dry eye disease therapy

A new antioxidant made from a pterostilbene functionalized graphene nanocomposite as an efficient treatment for dry eye disease

In Situ Scavenging of Mitochondrial ROS by Anti-Oxidative MitoQ/hyaluronic Acid Nanoparticles for Environment-Induced Dry Eye Disease Therapy

Highly effective corneal permeability of reactive oxygen species-responsive nano-formulation encapsulated cyclosporine a for dry eye management

Preparation and characterization of a naringenin solubilizing glycyrrhizin nanomicelle ophthalmic solution for experimental dry eye disease

WAY-100635 Alleviates Corneal Lesions Through 5-HT1A Receptor-ROS-Autophagy Axis in Dry Eye

Anti-oxidative and mucin-compensating dual-functional nano eye drops for synergistic treatment of dry eye disease

Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage

Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious Cycle

Multifunctional cerium oxide nanozymes with high ocular surface retention for dry eye disease treatment achieved by restoring redox balance

Engineering Ultra‐Small Cerium‐Based Metal–Organic Frameworks Nanozymes for Efficient Antioxidative Treatment of Dry Eye Disease

Reactive oxygen species activated NLRP3 inflammasomes prime environment-induced murine dry eye.

Corneal Mucin‐Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation

Multifunctional Cerium Oxide Nanozyme for Synergistic Dry Eye Disease Therapy

Evaluating the Efficacy of Polyglycolic Acid-Loading Tetrandrine Nanoparticles in the Treatment of Dry Eye